Henry Schein, Inc. $HSIC Stock Holdings Trimmed by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its position in Henry Schein, Inc. (NASDAQ:HSIC) by 17.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 5,101,448 shares of the company’s stock after selling 1,107,322 shares during the period. JPMorgan Chase & Co.’s holdings in Henry Schein were worth $385,568,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HSIC. AQR Capital Management LLC increased its holdings in Henry Schein by 47.3% in the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after buying an additional 9,756 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Henry Schein by 1.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after purchasing an additional 229 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Henry Schein during the first quarter valued at approximately $676,000. Cetera Investment Advisers grew its holdings in shares of Henry Schein by 12.9% during the second quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock valued at $406,000 after purchasing an additional 637 shares during the last quarter. Finally, First Trust Advisors LP grew its holdings in shares of Henry Schein by 0.8% during the second quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock valued at $16,154,000 after purchasing an additional 1,669 shares during the last quarter. 96.62% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Henry Schein news, Director William K. Daniel bought 10,000 shares of Henry Schein stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the acquisition, the director directly owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. This trade represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas C. Popeck sold 1,355 shares of the stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $72.79, for a total value of $98,630.45. Following the completion of the sale, the chief executive officer owned 86,182 shares of the company’s stock, valued at $6,273,187.78. The trade was a 1.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.89% of the stock is owned by corporate insiders.

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $78.85 on Thursday. The stock has a fifty day moving average of $75.07 and a 200-day moving average of $76.13. The company has a market capitalization of $8.98 billion, a PE ratio of 23.82, a price-to-earnings-growth ratio of 1.54 and a beta of 0.82. Henry Schein, Inc. has a one year low of $61.94 and a one year high of $89.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. The company had revenue of $3.37 billion during the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The company’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities analysts anticipate that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on HSIC shares. Wells Fargo & Company increased their price objective on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. UBS Group restated a “neutral” rating and issued a $85.00 target price (down from $87.00) on shares of Henry Schein in a research report on Wednesday, May 6th. Citigroup started coverage on Henry Schein in a research report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 target price for the company. Morgan Stanley reiterated an “underweight” rating and set a $64.00 price objective (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Finally, Leerink Partners reiterated a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $86.83.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.